Clinical Observation on the Target Therapy of Rh-Endostin, Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer
Background and objective The chemotherapy of advanced non-small cell lung cancer is in a Bottleneck. The target therapy of Anti-angiogenesis gradually shows an advantage in the therapy of patients with advanced NSCLC. To investigate the short-term efficacy, safety and the quality of life of the targ...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2009-07-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.07.007&path[]=947 |
| _version_ | 1811295807293358080 |
|---|---|
| author | Yiling FENG Chunyan SHEN Haiyu MU |
| author_facet | Yiling FENG Chunyan SHEN Haiyu MU |
| author_sort | Yiling FENG |
| collection | DOAJ |
| description | Background and objective The chemotherapy of advanced non-small cell lung cancer is in a Bottleneck. The target therapy of Anti-angiogenesis gradually shows an advantage in the therapy of patients with advanced NSCLC. To investigate the short-term efficacy, safety and the quality of life of the target therapy of rh-Endostin combined with chemotherapy in patients with advanced NSCLC. Methods Sixty-two advanced NSCLC patients were randomly divided into either the trial group with chemotherapy plus rh-Endostin or control group with chemotherapy alone. The efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria. Results The trial groups efficiency rate was 46.87%, while the control group was 26.66%, there was no significant differences of two groups (χ2=1.912, P=0.166). The clinical benefit rate was 81.25% in the trial group and 53.33% in control group. There was significant difference of the clinical benefit rate between the trial group and the control group (χ2=4.3185, P=0.0377). The score of quality of life in the trial group was significantly higher than that the control group after the treatment (χ2=11.233, P=0.0008). There was no significant difference of incidence of toxicities between the trial group and the control group (P>0.05). Conclusion Rh-Endostin combined with chemotherapy was effective, reasonable, safe and well tolerated for advanced NSCLC. |
| first_indexed | 2024-04-13T05:39:01Z |
| format | Article |
| id | doaj.art-fada5250107c4c3bbcfa9d3cc76b3fce |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-04-13T05:39:01Z |
| publishDate | 2009-07-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-fada5250107c4c3bbcfa9d3cc76b3fce2022-12-22T03:00:11ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872009-07-01127780784Clinical Observation on the Target Therapy of Rh-Endostin, Combined with Chemotherapy in Advanced Non-Small Cell Lung CancerYiling FENGChunyan SHENHaiyu MUBackground and objective The chemotherapy of advanced non-small cell lung cancer is in a Bottleneck. The target therapy of Anti-angiogenesis gradually shows an advantage in the therapy of patients with advanced NSCLC. To investigate the short-term efficacy, safety and the quality of life of the target therapy of rh-Endostin combined with chemotherapy in patients with advanced NSCLC. Methods Sixty-two advanced NSCLC patients were randomly divided into either the trial group with chemotherapy plus rh-Endostin or control group with chemotherapy alone. The efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria. Results The trial groups efficiency rate was 46.87%, while the control group was 26.66%, there was no significant differences of two groups (χ2=1.912, P=0.166). The clinical benefit rate was 81.25% in the trial group and 53.33% in control group. There was significant difference of the clinical benefit rate between the trial group and the control group (χ2=4.3185, P=0.0377). The score of quality of life in the trial group was significantly higher than that the control group after the treatment (χ2=11.233, P=0.0008). There was no significant difference of incidence of toxicities between the trial group and the control group (P>0.05). Conclusion Rh-Endostin combined with chemotherapy was effective, reasonable, safe and well tolerated for advanced NSCLC.http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.07.007&path[]=947rh-EndostinTarget therapyLung neoplasmsChemotherapy |
| spellingShingle | Yiling FENG Chunyan SHEN Haiyu MU Clinical Observation on the Target Therapy of Rh-Endostin, Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer Chinese Journal of Lung Cancer rh-Endostin Target therapy Lung neoplasms Chemotherapy |
| title | Clinical Observation on the Target Therapy of Rh-Endostin, Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| title_full | Clinical Observation on the Target Therapy of Rh-Endostin, Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| title_fullStr | Clinical Observation on the Target Therapy of Rh-Endostin, Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| title_full_unstemmed | Clinical Observation on the Target Therapy of Rh-Endostin, Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| title_short | Clinical Observation on the Target Therapy of Rh-Endostin, Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| title_sort | clinical observation on the target therapy of rh endostin combined with chemotherapy in advanced non small cell lung cancer |
| topic | rh-Endostin Target therapy Lung neoplasms Chemotherapy |
| url | http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.07.007&path[]=947 |
| work_keys_str_mv | AT yilingfeng clinicalobservationonthetargettherapyofrhendostincombinedwithchemotherapyinadvancednonsmallcelllungcancer AT chunyanshen clinicalobservationonthetargettherapyofrhendostincombinedwithchemotherapyinadvancednonsmallcelllungcancer AT haiyumu clinicalobservationonthetargettherapyofrhendostincombinedwithchemotherapyinadvancednonsmallcelllungcancer |